Peptides represent a billion-dollar market in the pharmaceutical industry, but they can generally only be taken as injections to avoid degradation by stomach enzymes. Scientists at EPFL have now developed a method to generate peptides that resist enzymatic degradation and can be taken orally.
Peptides are short chains of amino acids that occur in our body, in plants or bacteria to control diverse functions. Several peptides are used as drugs such as insulin, which controls the metabolism of sugar, and cyclosporine, which suppresses organ rejection after transplants. More than 40 peptides are already approved as drugs, generating revenues in the billions. There are several hundreds of peptide-based medications currently in clinical trials.
But almost none of these drug-peptides can be taken orally. Since peptides are an important part of food, the stomach and intestines harbor countless enzymes that can degrade them, meaning that most peptide-based medication do not survive the passage through the gastrointestinal tract.
Hope to generate more stable peptides came from “cyclic” peptides, whose ends are joined together by chemical bridges making them more stable than linear ones because their backbones are less flexible and thus harder to attack by enzymes. In 2018, the research group of Christian Heinis at EPFL developed a peptide format termed double-bridged peptides, where peptides are cyclized by two chemical bridges that provide even higher stability. Despite its success, most such peptides were not sufficiently stable to survive the enormous enzymatic pressure found in the gastrointestinal tract.
Now, Heinis’s group has developed a new method that identifies among billions of double-bridged peptides those that bind a disease target of interest and survive enzymes of the gastrointestinal tract. The method is published in Nature Biomedical Engineering, and involves three steps.
First, billions of genetically encoded random peptide sequences are cyclized by two chemical bridges that impose conformational constraints onto the peptides’ backbones so that they are more difficult to attack by enzymes.
Second, this library of peptides is exposed to enzymes from cow intestine to eliminate all those peptides that are not stable.
In the third and last step, the scientist dip target proteins into the pool of surviving peptides to fish out those that bind to the wanted disease target. “It’s a bit like searching a needle in a haystack, and this method makes this easy,” says Heinis.
With this method, the researchers have succeeded for the first time in evolving target-specific peptides that can resist breakdown in the gastrointestinal tract. For example, they gave mice a lead peptide that inhibits thrombin – an important anti-thrombosis target – in the form of a pill. The peptide remained intact in the stomach and intestines, and even though it reached the blood stream in rather small quantities, most of it remained fully intact across the entire gastrointestinal tract. This is a key step towards engineering oral peptide drugs.
Heinis’s group is now applying the new method to develop oral peptides that act directly on gastrointestinal targets, meaning that they don’t need to travel into the blood stream. “We are focusing on chronic inflammatory diseases of the gastrointestinal tract like Crohn’s disease and ulcerative colitis as well as bacterial infections,” says Heinis. “We have already succeeded in generating enzyme-resistant peptides against the interleukin-23 receptor, an important target of these diseases, which affect millions of patients worldwide without any oral drug available.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summiton April 15, 2021 at 3:32 pm
ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new ...
- Peptide Therapeutics Market 2015-2025 Global Analysis, Size, Share, Incredible Growth, Detailed Industry Analysis and Business Prospects | FMIon April 15, 2021 at 11:18 am
A recent market study published by Future Market Insights - " Peptide Therapeutics Market: Global Industry Analysis & Opportunity Assessment, 2015-2025 " consists a comprehensive assessment of the ...
- Booming CAGR of 32.8%, Oral Biologics Market to Surpass US$ 8,087.5 Mn Threshold by 2027 | Coherent Market Insightson April 14, 2021 at 6:32 am
Final Report will add the analysis of the impact of COVID-19 on this industry.” Oral Biologics Market 2020 Global Industry Research report presents an in-depth analysis of the Oral Biologics market ...
- Natural treatment based on flour made with mealworms prevents diabeteson April 14, 2021 at 5:45 am
Scientists from the Bioreactors Research Group (BIO-110) of the University of Granada (UGR) have demonstrated that a natural treatment based on flour made from the insect Tenebrio molitor (more ...
- Natural treatment based on flour made from mealworms can help prevent Type II diabetes mellituson April 13, 2021 at 6:19 pm
Scientists from the Bioreactors Research Group of the University of Granada have demonstrated that a natural treatment based on flour made from the insect Tenebrio molitor (more commonly known as the ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADCon April 16, 2021 at 5:00 am
Peptron, Inc. ("Peptron", KOSDAQ: 087010), a South Korea-based biotech company, and Qilu Pharmaceutical ("Qilu"), a leading ...
- ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEson April 16, 2021 at 2:59 am
ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent.
- With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?on April 12, 2021 at 1:23 pm
A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.
- PolyPeptide Group plans IPO and listing on the Swiss Stock Exchangeon April 11, 2021 at 10:42 pm
PolyPeptide Group ("PolyPeptide" or "the Group") is a leading contract development and manufacturing organization (CDMO) for innovative clinical and approved commercial-stage peptide drug substances ...
- Peptide Based Infection Therapeutics Market Big Players Focusing On Product Advancements For Business Expansionon April 10, 2021 at 12:51 am
Peptide-based Infection Therapeutics Market - Drivers Increasing number of pipeline drugs is expected to drive peptide-based infection therapeutics market. For instance, in September 2018, BioAegis ...